Compare Natera Inc. Common Stock (NTRA) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Raytheon Technologies Corp — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Raytheon Technologies Corp trades at $188.47 (market cap $246.67B). The key difference: Raytheon Technologies Corp is far larger — about 4.3× Natera Inc. Common Stock's market cap, and Raytheon Technologies Corp pays a 1.6% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Raytheon Technologies Corp for 78 Days on average.
| NTRA | RTX | |
|---|---|---|
Market Cap | $57.03B | $246.67B |
Volume | 1,131,157 | 4,726,714 |
Sector | Health | Industrials |
52-Week High | $425.64 | $225.49 |
52-Week Low | $179.42 | $157.00 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $56.18B | $277.22B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
RTX trades at $183.02, down 1.95% today, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.89 exceeding the $1.66 estimate. Revenue grew to $88.60 billion in 2025, and the net income margin improved to 7.59%. A robust $289 billion backlog and positive defense budget trends underpin growth prospects, though elevated debt levels and a high P/E ratio of 32.22 present valuation concerns.
The outlook remains positive given analyst consensus, with a $233.55 price target implying significant upside. Key opportunities include sustained defense demand and commercial aerospace recovery. Risks involve execution on the large backlog, interest expense from debt, and geopolitical uncertainties affecting defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
